Skip to main content
Premium Trial:

Request an Annual Quote

TriPath Agrees to $350M BD Acquisition; Deal Slated to Close in Q4

NEW YORK (GenomeWeb News) - TriPath Imaging said today that it has signed a definitive merger agreement with Becton, Dickinson, under which BD will acquire the 93.5 percent of outstanding TriPath shares that it does not currently own in a deal worth approximately $350 million.
 
BD announced its intent to acquire TriPath last month. The companies have been collaborating to identify cancer biomarkers since 2001, when BD acquired an approximately 6.5-percent equity stake in TriPath.
 
Under the terms of the acquisition agreement, BD will pay $9.25 for each share of TriPath Imaging common stock, an 81 percent premium to $5.12, TriPath’s closing share price on Aug. 14, when BD announced its proposal to acquire the firm.
 
The transaction is expected to close in the fourth quarter of 2006.
 
TriPath, based in Burlington, NC, develops and sells products for cancer diagnostics and treatment. The company’s TriPath Oncology subsidiary develops molecular diagnostic products for malignant melanoma and cancers of the cervix, breast, ovary, and prostate.

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.